Salesforce & IT Operations Manager

Neogen (NASDAQ:NEOG) shares gap up after strong earnings. October 7, 2026 Key points. * Neogen exceeded quarterly expectations: Fiscal Q1 revenue rose 6.5% year over year to $222.8 million, above the $208.2 million consensus, while adjusted EPS came in at $0.08 versus the $0.05 estimate. * Management raised its outlook: Fiscal 2027 revenue guidance increased to $885 million-$890 million, with adjusted EBITDA projected at $181 million-$183 million. Food Safety revenue grew 7.4%, and Animal Safety revenue increased 4.2%. * Risks remain despite the positive earnings reaction: Neogen posted an $11.9 million net loss, while upcoming manufacturing changes, the proposed Genomics sale, and shareholder investigations related to the HYCOAT recall could create execution, legal, and reputational challenges. * Interested in Neogen? Here are five stocks we like better. Neogen Corporation (NASDAQ:NEOG - Get Free Report)'s share price gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $11.96, but opened at $12.61. Neogen shares last traded at $11.56, with a volume of 1,574,885 shares. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.05 by $0.03. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The company had revenue of $222.80 million for the quarter, compared to analysts' expectations of $208.18 million. During the same period last year, the firm posted $0.04 earnings per share. Neogen's revenue was up 6.5% compared to the same quarter last year. Key Neogen news. Here are the key news stories impacting Neogen this week: * Neogen reported fiscal Q1 revenue of $222.8 million, up 6.5% year over year and above the $208.2 million analyst estimate. Adjusted earnings were $0.08 per share versus the $0.05 consensus and $0.04 in the prior-year quarter. * Management raised fiscal 2027 revenue guidance to $885 million-$890 million, slightly above the $883.2 million consensus, and projected adjusted EBITDA of $181 million-$183 million. Food Safety revenue increased 7.4% to $163.2 million, while Animal Safety revenue rose 4.2% to $59.6 million. * The earnings update and outlook prompted reports that NEOG shares swung higher in premarket trading, reflecting investor confidence in sales growth and the raised forecast. * Neogen expects to begin a multi-quarter transition of Petrifilm manufacturing in November 2026. The change could support longer-term operations but introduces execution risk during the transition. The company also expects regulatory reviews of its proposed global Genomics sale to Zoetis to conclude by the end of December. * Despite the adjusted EPS beat, Neogen reported a $11.9 million net loss, or $0.05 per diluted share, compared with $36.3 million of net income a year earlier. Its reported net margin remained negative, which may limit enthusiasm if profitability does not improve. * Pomerantz and Levi & Korsinsky announced investigations related to shareholder claims, including the earlier HYCOAT equine-product warning and recall. These legal developments add reputational and potential financial risk. Wall Street analyst weigh in. NEOG has been the subject of a number of recent research reports. Weiss Ratings upgraded Neogen from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Neogen from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Guggenheim reaffirmed a "buy" rating and issued a $14.00 target price (up from $12.00) on shares of Neogen in a report on Wednesday, September 30th. Finally, Piper Sandler upgraded Neogen from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $13.00 to $14.00 in a research note on Wednesday, August 26th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $12.67. Discover more Stock research tools Institutional investors weigh in on Neogen. Several large investors have recently made changes to their positions in the company. Nykredit A S bought a new position in Neogen during the second quarter valued at approximately $28,000. Public Employees Retirement System of Ohio bought a new stake in Neogen in the 2nd quarter worth approximately $34,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Neogen during the 2nd quarter worth approximately $73,000. Sequoia Financial Advisors LLC bought a new position in Neogen during the second quarter valued at $94,000. Finally, Ieq Capital LLC purchased a new position in Neogen in the second quarter worth about $95,000. 96.73% of the stock is owned by institutional investors. Neogen trading down 3.3%. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.91 and a current ratio of 3.82. The stock has a fifty day moving average price of $12.08 and a 200 day moving average price of $10.25. The stock has a market cap of $2.52 billion, a PE ratio of -387.03, a PEG ratio of 4.88 and a beta of 1.79. Neogen company profile. Neogen Corporation is a global provider of food safety and animal safety products and services. The company develops diagnostic tests, laboratory products, and related solutions that help customers detect foodborne pathogens, allergens, toxins, residues, and other contaminants throughout the food production process. Its food safety portfolio includes test kits, culture media, molecular testing systems, sanitation monitoring products, and laboratory supplies used by food manufacturers, processors, retailers, and regulatory organizations. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Neogen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list. While Neogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America. Continue following MarketBeat

Neogen announces strategic collaboration with Hinalea Imaging to advance digital Food Safety solutions. Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. Companies to develop intelligent imaging solutions for food safety Neogen(R) Corporation (NASDAQ:NEOG), a global leader in food safety solutions, is advancing its innovation strategy by combining deep food safety expertise with emerging technologies to introduce novel solutions to the Food Safety industry that address evolving customer challenges. As part of that strategy, Neogen today announced a strategic collaboration with and an equity investment in Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection. Neogen and Hinalea have worked together since 2025 to evaluate applications for hyperspectral imaging in food safety. Building on that work, the companies plan to jointly develop solutions that could improve inspection and testing workflows and help customers interpret results faster and more consistently. Neogen's equity investment and shared development costs are intended to accelerate the development of Hinalea's technology for food safety applications. "Food producers need solutions that deliver reliable information sooner and reduce the manual work involved in testing and inspection," said Jeremy Yarwood, Chief Scientific Officer of Neogen. "We believe Hinalea's imaging technology offers a promising way to address those needs practically and economically. This investment provides an opportunity to deepen our collaboration and develop digital capabilities that bring Neogen's food safety expertise into new inspection workflows." Hyperspectral imaging captures information across a range of wavelengths to help assess product characteristics that conventional images may not reveal. Combined with analytical tools and machine learning, hyperspectral imaging has the potential to support more automated measurement, counting and classification in food safety and quality applications. The two companies will continue to evaluate where the technology can deliver meaningful benefits within customer workflows. "Food safety and quality inspection are shifting toward digital, connected and increasingly automated workflows," said Barry McDonogh, CEO of Hinalea Imaging. "Neogen's investment validates both our technology and our shared vision for the future of food inspection. Together, we believe intelligent imaging can transform how food companies measure and control food quality and safety." About Neogen Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers. About Hinalea Imaging Hinalea Imaging develops intelligent hyperspectral imaging solutions combining advanced spectral imaging, analytics and machine learning to enable enhanced and automated inspection. Its technology converts spectral information into actionable intelligence across food safety and quality, industrial inspection, healthcare and advanced manufacturing. For more information, visit www.hinalea.ai. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Neogen intends that such forward-looking statements be covered by the safe harbor provisions for forward-looking statements contained in the PSLRA. Forward-looking statements include, but are not limited to, all statements that are not historical facts, including, without limitation, statements containing a projection of revenues, operating expenses, planned capital expenditures, or other financial items; any statement of the plans and objectives of management for future operations; the ability of Neogen and Hinalea to jointly develop solutions that could automate parts of inspection and testing and help customers interpret results faster and more consistently; the potential benefits of the collaboration with and investment in Hinalea; the ability of Hinalea's hyperspectral imaging technology to address the needs of food producers and to transform how food companies measure and control food quality and safety; and any statement of the assumptions underlying or relating to any such statement. Words such as "anticipate," "believe," "can," "continue," "estimate," "expect," "may," "on track," "plan," "potential," "will," or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including, but not limited to: the continued integration of the 3M food safety business and the realization of the expected benefits from that acquisition; the relationship with and performance of our transition manufacturing partner; competition; recruitment and retention of key employees; impact of weather on agriculture and food production; global business disruption caused by geopolitical conflicts and related sanctions, such as the Russia-Ukraine war and the conflict in the Middle East; identification and integration of acquisitions; research and development risks; intellectual property protection; increasing and developing government regulation; and company litigation. These and other important risk factors are described more fully in the Risk Factors sections and other sections of Neogen's Annual Report on Form 10-K for the year ended May 31, 2026; Neogen's Quarterly Reports on Form 10-Q, and Neogen's other filings with the SEC, including any Current Reports on Form 8-K. In light of these risks and uncertainties, the events and circumstances discussed in such forward-looking statements may not occur, and Neogen's actual results could differ materially and adversely from those anticipated or implied thereby. There can be no assurance that the forward-looking statements contained in this press release will prove to be accurate. You are cautioned not to place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Neogen as of the date of this press release. Except as required by applicable law, Neogen does not undertake, and expressly disclaims, any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. If Neogen does update one or more forward-looking statements, no inference should be drawn that Neogen will make additional updates with respect to those or other forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release and in any oral statements made by or on behalf of Neogen.

Levi & Korsinsky notifies investors of pending investigation into securities claims involving Neogen (NEOG). An investigation is examining whether NEOG shareholders who lost money after the FDA warning on Neogen's recalled HYCOAT equine product may be able to recover those losses. Investors who have already sold their shares may still have rights. NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) - An FDA warning concerning HYCOAT, a recalled equine product sold under the Neogen Vet line, erased over 7% from Neogen Corporation (NASDAQ: NEOG) shares in a single trading session. NEOG shareholders who lost money on that move may have legal rights to seek recovery. Shareholders who suffered losses are encouraged to submit their NEOG loss information for review. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. According to reporting on the warning, FDA testing identified multiple fungal species in HYCOAT, a product marketed as sterile. Coverage cited nearly 100 affected horses and at least 20 horse deaths. On July 30, 2026, during Neogen's fiscal fourth-quarter earnings call, CEO Mikhael Nassif told investors the Company had "resolved prior supply and quality challenges." The investigation concerns potential securities law violations and whether NEOG shareholders may be entitled to recover losses tied to the HYCOAT warning. Shareholders who have already sold their NEOG shares may still be eligible. There is no upfront cost to have a potential loss reviewed. If you lost money on Neogen stock, request a free review of your shareholder rights or call Joseph E. Levi, Esq. at (212) 363-7500. Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com Frequently Asked Questions About the NEOG Investigation Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Neogen made potentially false or misleading statements about the condition of its Animal Safety business and the resolution of supply and quality challenges affecting its Neogen Vet product line. When the FDA warning on the recalled HYCOAT equine product became public, NEOG shares fell 7.22%. Q: When did Neogen allegedly mislead investors? A: The investigation concerns statements made before the FDA warning on HYCOAT that allegedly caused investors to buy NEOG securities at inflated prices. Q: What do NEOG investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation. Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option. Q: What if I already sold my NEOG shares - can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NEOG and sold at a loss may still participate in the investigation. Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. If you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval. Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence. Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 Attorney Advertising. Prior results do not guarantee similar outcomes.